MedTrace Logo

A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children

NCT00514033 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 349

Last updated 2012-03-19

No results posted yet for this study

Summary

Following licensing of PoliorixTM in Korea, this study will collect safety data about the routine use of this vaccine in 600 children according to the regulations of Korean Food and Drugs Administration (KFDA).

Conditions

  • Poliomyelitis

Interventions

BIOLOGICAL

Poliomyelitis vaccine (inactivated) -PoliorixTM

Deep intramuscular injections for the primary vaccination and booster vaccination.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
2 Months
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514033 on ClinicalTrials.gov